Glycosylation and Lysosomal Storage Diseases

Protein Processing and Glycosylation in the ER and Golgi

• The processing of prebuilt oligosaccharides begins in the rough endoplasmic reticulum (ER) and continues in the Golgi apparatus.

• The oligosaccharide structure initially consists of glucose (red diamonds), mannose (blue pyramids/triangles), and $GlcNAc$ ($N\text{-acetylglucosamine}$, yellow dots).

• In the rough ER, glucose residues are removed to expose mannose, which is a critical step for targeting proteins to the lysosomes.

• The specific pathway taken by a protein is likely determined by amino acid sequences that enzymes recognize during glycosylation.

The Mannose-6-Phosphate (M6P) Tagging Pathway

• Proteins destined for lysosomes undergo a specific two-step modification process in the Golgi to create the $M6P$ tag:

  • Step 1: The enzyme identifies the protein and adds phosphorylated $GlcNAc$ to the mannose. This involves $UDP\text{-}N\text{-acetylglucosamine}$ ($UDP\text{-}GlcNAc$), where the enzyme removes the uridine and one phosphate to attach the remaining phosphate and $GlcNAc$ to the mannose.

  • Step 2: A second enzyme removes the $GlcNAc$ moiety, leaving the phosphate on the sixth carbon of the mannose, resulting in $Mannose\text{-}6\text{-phosphate}$ ($M6P$).

• The $M6P$ modification serves as a "secondary address" signal; the more $M6P$ tags present, the stronger the signal for lysosomal transport.

Trafficking and Receptor-Mediated Sorting

• Within the Golgi, the $M6P$ tag acts as a ligand for the $M6P$ receptor.

• Receptors bind the tagged proteins and cluster them into sections of the Golgi that bud off into transport vesicles.

• These vesicles travel to a sorting vesicle (also known as a recycling endosome or formerly $CURL$ - compartment of uncoupling receptor and ligand).

• In the acidic environment of the sorting vesicle, the receptor releases the $M6P$ protein and is recycled back to the Golgi.

• The proteins are then delivered to the lysosomes, where the phosphate tag may be removed due to the acidic pH.

• A fail-safe system exists in some cells, such as liver cells, which have $M6P$ receptors on the cell surface to recover lysosomal enzymes that were accidentally secreted.

Lysosomal Storage Diseases

• Mucolipidosis Type II (ML2 / I-cell Disease / Leroy Disease):

  • An autosomal recessive disorder caused by a deficiency in the first enzyme of the tagging pathway ($GNPTAB$ or $GMP\,TAP$).

  • Because the $M6P$ tag cannot be created, lysosomal enzymes are secreted instead of delivered to the lysosomes.

  • Symptoms include musculoskeletal abnormalities, inclusion bodies (hence "I-cell"), and developmental plateaus.

  • Interestingly, the heart typically functions normally in these patients, suggesting alternative tagging mechanisms may exist in cardiac tissue.

• Mucolipidosis Type I (Hurler Syndrome) and Type III (Pseudo-Hurler): Related disorders within the same family of diseases.

• Tay-Sachs Disease: A well-known and manageable lysosomal storage disease.

• Niemann-Pick Disease (NPC): A cholesterol storage disease primarily affecting neurons, leading to motor function decline.

Therapeutic Innovations: Cyclodextrin

• Cyclodextrin, the active ingredient in Febreze, has shown success in treating Niemann-Pick disease.

• It works by "caging" organic matter (cholesterol) in its molecular structure, allowing it to be cleared from the cells.

• Treatments involve infusions into the cerebrospinal fluid or intravenous delivery to reduce symptoms and clear accumulations.